The pharmaceutical company Pfizer updated today (Tuesday) its evaluations regarding the effectiveness of the drug it developed against coronary heart disease and claimed that the treatment is 89 percent effective in preventing mortality or hospitalization among adults who are at risk.
The drug, which the drug giant intends to market under the name "Paxlobid", is intended for home use for adults in the risk group who have been diagnosed as positive for the virus but do not yet need hospitalization.
The drug combines a new antiviral substance called nirmaltarbir, and an older substance called ritonavir.
Pfizer CEO Albert Burla, Photo: AP
After a follow-up study on the period for about a month, Pfizer claims that no deaths were recorded among the 697 study participants in the first three days of coronary heart disease symptoms.
Of the control group, which included 682 placebo recipients, nine died and nearly fifty were hospitalized.
All trial participants were unvaccinated.
In a statement issued by Pfizer CEO Albert Burla, he claimed that the viral load among the recipients of the drug was ten times lower than among the members of the placebo group.
"This shows the potential of the drug to save lives among the most vulnerable groups of coronary heart disease," Burla curated in a brief statement to the media.
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us